For decades, the crowds outside House of Nanking have been a fixture of San Francisco’s Chinatown, with lines frequently wrapping around the block to get a seat in the cramped, high-energy dining room, under the iconic, multicolored sign that crowns Kearny Street. But for Kathy Fang, the restaurant’s heir apparent, her presence in that kitchen represents a sharp deviation from the “American Dream” her parents envisioned for her—a deviation that initially caused them deep dismay.Peter Fang, the restaurant’s ...

Group 1 - The article discusses the expertise of Fred Piard, a quantitative analyst with over 30 years in technology, focusing on data-driven systematic investment strategies since 2010 [1] - Fred Piard manages an investing group called Quantitative Risk & Value, which emphasizes quality dividend stocks and innovative tech companies [1] - The article highlights that Fred provides various market risk indicators and investment strategies, including real estate, bonds, and income strategies in closed-end funds [1]

Core Insights - Johnson & Johnson announced promising results from the Phase 1b/2 OrigAMI-1 study of amivantamab combined with chemotherapy for RAS/BRAF wild-type metastatic colorectal cancer, showing over 70% response rates in the first-line subgroup and durable responses lasting beyond 16 months [1][2][5] Study Results - The study demonstrated a confirmed overall response rate (ORR) of 51% across all patients, with a median duration of response (DOR) of 9.3 months and a median progression-free survival (PFS) of 9.2 months [5][6] - In the first-line subgroup, the ORR was 73%, with some patients maintaining responses for over two years, and four patients proceeding to curative intent surgery [5][6] - Notable activity was observed in patients with liver metastases, achieving an ORR of 57% and a median PFS of 11.3 months [6] Safety Profile - The safety profile of amivantamab plus chemotherapy was consistent with previous reports, with treatment-related adverse events primarily linked to EGFR and MET inhibition [6] - Only 9% of patients discontinued therapy due to treatment-related adverse events, with neutropenia being the most common Grade 3 or higher event [6] Future Directions - Johnson & Johnson is advancing pivotal Phase 3 studies (OrigAMI-2 and OrigAMI-3) to further evaluate amivantamab-based regimens in both first- and second-line colorectal cancer settings [7]

Core Insights - Eli Lilly and Johnson & Johnson both reported strong third-quarter results, indicating robust performance in their respective healthcare sectors [1] Company Performance - Eli Lilly and Johnson & Johnson demonstrated fundamentally different healthcare business models despite both achieving strong earnings [1]

Core Insights - The "High-Income DIY Portfolios" Marketplace service aims to provide high income with low risk and capital preservation for DIY investors, particularly targeting income investors such as retirees or near-retirees [1][2] - The service offers a total of 10 model portfolios, including 3 buy-and-hold, 3 rotational portfolios, and a conservative NPP strategy portfolio, designed to create stable, long-term passive income with sustainable yields [1][2] Group 1 - The service includes two High-Income portfolios, two Dividend Growth Investing (DGI) portfolios, and a conservative NPP strategy portfolio that focuses on low drawdowns and high growth [1] - The unique 3-basket investment approach aims for 30% lower drawdowns, 6% current income, and market-beating growth over the long term [2] - The portfolios are structured to cater to varying levels of risk and include buy and sell alerts along with live chat support for investors [2]

It was a tough summer for shares of Kenvue Inc. ( KVUE ), the personal care company spun off from Johnson & Johnson ( JNJ ) in 2023. From June through October, theI retired early after 22 years in the energy industry with roles in engineering, planning, and financial analysis. I have managed my own portfolio since 1998 and have met my goal to match the S+P 500 return over the long term with lower volatility and higher income. I mostly write on positions I already hold or am considering changing. I prefer to ...

ipopba / iStock via Getty Images Quick Read FHLC charges just 0.084% in fees but carries 13% concentration in Eli Lilly. The fund gained 17.9% over one year but returned only 154% over ten years versus the S&P 500’s 235%. Enhanced ACA premium tax credits face 87.5% probability of expiring by January 31 2026. Have You read The New Report Shaking Up Retirement Plans? Americans are answering three questions and many are realizing they can retire earlier than expected. Healthcare investing offers ...

Core Insights - Healthcare investing is characterized by defensive traits during market volatility, but regulatory and political risks can lead to abrupt selloffs [1] - Fidelity MSCI Health Care Index ETF (FHLC) offers a low-cost entry point for investors seeking exposure to the healthcare sector without selecting individual stocks [1] Fund Overview - FHLC tracks the MSCI USA IMI Health Care Index, providing exposure to U.S. healthcare companies across various segments including pharmaceuticals, biotechnology, medical devices, and health insurance [2] - The fund has an expense ratio of 0.084% and includes over 80 holdings, focusing on capital appreciation and modest dividend income [2] Concentration Risk - Eli Lilly constitutes over 13% of FHLC's portfolio, linking its performance closely to GLP-1 obesity drugs, which have seen a 46% increase in stock price over the past year [3] - The top five holdings also include UnitedHealth, Johnson & Johnson, Merck, and AbbVie [3] Performance Analysis - FHLC has shown strong short-term performance, gaining 5.3% in the last month and 17.9% over the past year, outperforming the S&P 500 [4] - However, over five years, FHLC returned 42.6%, significantly lagging behind the S&P 500's 84.5% return, with a widening gap over ten years (154% vs. 235%) [4] Sector Challenges - The underperformance of FHLC reflects broader challenges in the healthcare sector, including drug pricing pressures and slower innovation cycles outside oncology and rare diseases [5] - Recent momentum may indicate potential sector rotation, but investing after outperformance carries inherent risks [5] Policy and Income Considerations - Investors face political and regulatory uncertainties, with an 87.5% probability that enhanced ACA premium tax credits will expire by January 2026, impacting health insurers like UnitedHealth [7] - FHLC's yield of 1.33% is considered modest compared to other market alternatives, with dividend growth of approximately 4.6% annually over five years, barely keeping pace with inflation [8] Suitability for Investors - Growth-focused investors seeking maximum capital appreciation may find FHLC unsuitable due to its long-term underperformance [9] - Retirees prioritizing income generation may also find better yield opportunities in other sectors without sacrificing stability [9] Alternative Options - Vanguard Health Care ETF (VHT) is presented as an alternative, with a slightly higher expense ratio of 0.09%, larger asset base of $20.4 billion, and a higher dividend yield of 1.38% [11] - VHT's longer track record since 2004 and superior liquidity may provide additional confidence for long-term investors [11] Tactical Allocation - FHLC may serve as a tactical allocation for investors seeking low-cost exposure to the healthcare sector, but concentration risk and historical underperformance necessitate careful position sizing [12]

Company - Nvidia is recruiting executives from Google Cloud to strengthen its position in the market [8] - Chevron could see an annual revenue increase of up to $700 million due to its operations in Venezuela [8] - Stellantis has canceled its sales plan for plug-in hybrid vehicles in the U.S. due to weak demand [8] - Glencore and Rio Tinto are in negotiations to potentially create the world's largest mining company [8] - xAI plans to invest $20 billion in building a data center in Mississippi [8] - Hyundai will fully deploy humanoid robots starting in 2028 [8] - Paramount reiterated its all-cash offer of $30 per share for WBD [8] - General Motors will account for $7.1 billion in expenses in the fourth quarter [8] - Johnson & Johnson is lowering drug prices in the U.S. in exchange for tariff reductions, but experts say savings for insured individuals will be limited [8] Industry - The U.S. added 584,000 jobs in 2025, marking the lowest growth rate in a non-recession period since 2003 [8] - U.S. household wealth has reached a record high, benefiting from the rise in the stock market [8] - The EU is expected to sign a historic trade agreement with South America despite opposition from France [8] - The WTI crude oil price has risen for the third consecutive week [9] - The U.S. debt market shows mixed results, with a flattening yield curve and mixed non-farm payroll data [9] - The dollar is rising alongside U.S. Treasury yields as traders reduce bets on Federal Reserve rate cuts [9]

Key Points AbbVie and Johnson & Johnson have resilient, noncyclical businesses. They are also outstanding dividend payers. 10 stocks we like better than AbbVie › The technology sector is an excellent place to find high-growth stocks with promising prospects. However, it is a cyclical sector that doesn't perform as well when the economy tanks. It's critical for investors to diversify their tech holdings, perhaps by putting their money into more defensive industries that behave differently during dow ...